Objective: To ascertain the relationship between tea drinking and the risk of ovarian cancer among southern Chinese women, a case-control study was conducted in southern China during 2006-2008.
Methods: Five hundred incident patients with histologically confirmed epithelial carcinoma of the ovary and 500 controls (mean age 59 years) were recruited from four public hospitals in Guangzhou. Information on frequency, quantity and duration of tea drinking, amount of dried tea leaves brewed, together with habitual diet and lifestyle characteristics, was obtained face-to-face from participants using a validated and reliable questionnaire. Logistic regression analyses were performed to assess the association between tea consumption variables and the ovarian cancer risk.
Results: The control subjects reported higher tea consumption levels and prevalence (78.8%) than the ovarian cancer patients (51.4%). Regular drinking of green tea, black tea and/or oolong tea was associated with a lower risk of ovarian cancer, the adjusted odds ratio being 0.29 (95% confidence interval 0.22-0.39) after accounting for confounding factors. When compared with non-drinkers, apparent inverse dose-response relationships were observed for years of drinking, number of cups and quantity of tea consumed, as well as amount of dried tea leaves brewed (p < 0.01).
Conclusion: Regular tea consumption is associated with a reduced risk of ovarian cancer for southern Chinese women.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.canep.2012.10.003 | DOI Listing |
Int J Gynecol Pathol
January 2025
Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, California.
Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a rare, typically benign uterine tumor occurring over a wide age range (mean 52.4 yr). UTROSCTs often harbor translocations between ESR1 and nuclear receptor coactivators NCOA1-NCOA3.
View Article and Find Full Text PDFInt J Gynecol Pathol
January 2025
Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School.
Ovarian clear cell carcinoma (OCCC) is an endometriosis-related neoplasm, in which traditional histologic grading does not show prognostic significance. Tumor budding was associated with poorer outcomes in OCCC in previous studies. We aimed to evaluate the prognostic significance of tumor budding in OCCC in an independent cohort.
View Article and Find Full Text PDFCancer Invest
January 2025
Psychology Department, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto-SP, Brazil.
Although breast, cervical, endometrial, and ovarian cancers account for more than 43% of new cases in 2023 in Brazilian women, no national studies were found on the incidence, risk factors, and prevention of breast and gynecological neoplasms in lesbian women, causing the health needs of non-heterosexual women to go unnoticed by professionals. This study aims to identify and analyze the search for healthcare related to the prevention of breast/gynecological cancer among Brazilian lesbian cisgender women who have not had the disease. Seven lesbian women participated in this qualitative study.
View Article and Find Full Text PDFMol Cancer Ther
January 2025
Tango Therapeutics (United States), Boston, United States.
Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on poly(ADP-ribose) polymerase (PARP) inhibitors, which are subject to high rates of innate or acquired resistance in patients. Here, we used CRISPR/Cas9-based screening to identify DNA Ligase I (LIG1) as a novel target for synthetic lethality in BRCA1-mutated cancers. Publicly available data supported LIG1 hyperdependence of BRCA1-mutant cells across a variety of breast and ovarian cancer cell lines.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Objective: To compare the effects of different treatment modes containing PARPis and traditional treatment modes on the survival of patients with recurrent ovarian cancer.
Methods: From December 2012 to December 2023, 131 recurrent ovarian cancer patients were screened. The patients were followed up retrospectively, and the relevant data was collected and analyzed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!